Asio Capital LLC Cuts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Asio Capital LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 59.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,304 shares of the medical research company’s stock after selling 6,233 shares during the quarter. Asio Capital LLC’s holdings in IQVIA were worth $846,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Capital Performance Advisors LLP bought a new position in IQVIA during the 3rd quarter valued at about $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA during the third quarter valued at approximately $28,000. Avior Wealth Management LLC lifted its position in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. boosted its holdings in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after buying an additional 99 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.7 %

Shares of NYSE IQV opened at $204.54 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm’s 50-day moving average price is $199.71 and its 200-day moving average price is $221.06. The stock has a market capitalization of $37.12 billion, a price-to-earnings ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48.

Analyst Ratings Changes

Several equities research analysts have recently commented on IQV shares. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group cut their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Finally, BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.